NYSE:CRL

Charles River Laboratories International Stock Forecast, Price & News

$327.70
+3.68 (+1.14 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$322.85
Now: $327.70
$331.16
50-Day Range
$268.16
MA: $293.92
$324.59
52-Week Range
$133.57
Now: $327.70
$331.16
Volume369,448 shs
Average Volume319,943 shs
Market Capitalization$16.45 billion
P/E Ratio54.62
Dividend YieldN/A
Beta1.12
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Charles River Laboratories International logo

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP15986410
Phone781-222-6000
Employees18,400
Year Founded1947

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.62 billion
Cash Flow$13.02 per share
Book Value$33.45 per share

Profitability

Net Income$252.02 million

Miscellaneous

Market Cap$16.45 billion
Next Earnings Date5/4/2021 (Confirmed)
OptionableOptionable

Headlines

Charles River Laboratories Acquires Retrogenix
March 31, 2021 |  finance.yahoo.com
Is CRL Stock A Buy or Sell?
March 29, 2021 |  finance.yahoo.com
Look for the Rally in Charles River Labs to Continue
February 24, 2021 |  finance.yahoo.com
Charles River: Q4 Earnings Insights
February 17, 2021 |  benzinga.com
See More Headlines

MarketRank

Overall MarketRank

1.34 out of 5 stars

Medical Sector

745th out of 2,024 stocks

Commercial Physical Research Industry

15th out of 42 stocks

Analyst Opinion: 1.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
$327.70
+3.68 (+1.14 %)
(As of 04/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRL News and Ratings via Email

Sign-up to receive the latest news and ratings for CRL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Charles River Laboratories International (NYSE:CRL) Frequently Asked Questions

Is Charles River Laboratories International a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories International in the last twelve months. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Charles River Laboratories International stock.
View analyst ratings for Charles River Laboratories International
or view top-rated stocks.

What stocks does MarketBeat like better than Charles River Laboratories International?

Wall Street analysts have given Charles River Laboratories International a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Charles River Laboratories International wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Charles River Laboratories International's next earnings date?

Charles River Laboratories International is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Charles River Laboratories International
.

How can I listen to Charles River Laboratories International's earnings call?

Charles River Laboratories International will be holding an earnings conference call on Tuesday, May 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Charles River Laboratories International's earnings last quarter?

Charles River Laboratories International, Inc. (NYSE:CRL) announced its quarterly earnings data on Tuesday, February, 16th. The medical research company reported $2.39 earnings per share for the quarter, beating the Zacks' consensus estimate of $2.11 by $0.28. The medical research company earned $790.99 million during the quarter, compared to analyst estimates of $755.98 million. Charles River Laboratories International had a net margin of 10.68% and a trailing twelve-month return on equity of 22.41%.
View Charles River Laboratories International's earnings history
.

How has Charles River Laboratories International's stock been impacted by COVID-19 (Coronavirus)?

Charles River Laboratories International's stock was trading at $136.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRL shares have increased by 139.9% and is now trading at $327.70.
View which stocks have been most impacted by COVID-19
.

What guidance has Charles River Laboratories International issued on next quarter's earnings?

Charles River Laboratories International issued an update on its FY 2021 Pre-Market earnings guidance on Wednesday, February, 17th. The company provided earnings per share (EPS) guidance of 9.00-9.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.86. The company issued revenue guidance of $3.275-3.333 billion, compared to the consensus revenue estimate of $3.19 billion.

What price target have analysts set for CRL?

14 brokers have issued 1 year price targets for Charles River Laboratories International's stock. Their forecasts range from $175.00 to $350.00. On average, they expect Charles River Laboratories International's stock price to reach $254.71 in the next twelve months. This suggests that the stock has a possible downside of 22.3%.
View analysts' price targets for Charles River Laboratories International
or view top-rated stocks among Wall Street analysts.

Who are Charles River Laboratories International's key executives?

Charles River Laboratories International's management team includes the following people:
  • Mr. James C. Foster, Chairman, CEO & Pres (Age 70, Pay $5.38M) (LinkedIn Profile)
  • Mr. David Ross Smith, Corp. Exec. VP & CFO (Age 55, Pay $1.25M) (LinkedIn Profile)
  • Mr. Joseph W. LaPlume, Corp. Exec. VP of Corp. Devel. & Strategy (Age 47, Pay $931.56k) (LinkedIn Profile)
  • Ms. Birgit Girshick, Corp. EVP of Global Discovery & Safety Assessment, Biologics Testing Solutions & Avian Vaccine (Age 51, Pay $937.58k) (LinkedIn Profile)
  • Mr. Michael Gunnar Knell, Corp. Sr. VP & Chief Accounting Officer (Age 44)
  • Mr. Arthur C. Hubbs, Corp. Sr. VP & Chief Information Officer (LinkedIn Profile)
  • Todd Spencer, Corp. VP of Investor Relations
  • Mr. Matthew L. Daniel, Corp. Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (LinkedIn Profile)
  • Ms. Amy Cianciaruso, Corp. VP of PR & Corp. Communications
  • Ms. Gina M. Mullane, Chief Marketing Officer & Corp. Sr. VP (LinkedIn Profile)

What is James C. Foster's approval rating as Charles River Laboratories International's CEO?

291 employees have rated Charles River Laboratories International CEO James C. Foster on Glassdoor.com. James C. Foster has an approval rating of 75% among Charles River Laboratories International's employees.

Who are some of Charles River Laboratories International's key competitors?

What other stocks do shareholders of Charles River Laboratories International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories International investors own include NVIDIA (NVDA), The Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), salesforce.com (CRM), Abbott Laboratories (ABT), Mastercard (MA), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

What is Charles River Laboratories International's stock symbol?

Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

Who are Charles River Laboratories International's major shareholders?

Charles River Laboratories International's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Confluence Investment Management LLC (0.39%), Riverbridge Partners LLC (0.31%), Retirement Systems of Alabama (0.23%), Boston Trust Walden Corp (0.15%), New York State Teachers Retirement System (0.14%) and Mountain Pacific Investment Advisers Inc. ID (0.14%). Company insiders that own Charles River Laboratories International stock include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Richard F Wallman, Robert J Bertolini, Stephen D Chubb and William D Barbo.
View institutional ownership trends for Charles River Laboratories International
.

Which institutional investors are selling Charles River Laboratories International stock?

CRL stock was sold by a variety of institutional investors in the last quarter, including New York State Teachers Retirement System, Private Advisor Group LLC, Landsberg Bennett & Dubbaneh LLC, BOKF NA, Gateway Investment Advisers LLC, Confluence Investment Management LLC, Crossmark Global Holdings Inc., and Zeke Capital Advisors LLC. Company insiders that have sold Charles River Laboratories International company stock in the last year include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Robert J Bertolini, Stephen D Chubb, and William D Barbo.
View insider buying and selling activity for Charles River Laboratories International
or view top insider-selling stocks.

Which institutional investors are buying Charles River Laboratories International stock?

CRL stock was purchased by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Boston Trust Walden Corp, Mountain Pacific Investment Advisers Inc. ID, FDx Advisors Inc., Exchange Traded Concepts LLC, Bellecapital International Ltd., State of Alaska Department of Revenue, and LVW Advisors LLC.
View insider buying and selling activity for Charles River Laboratories International
or or view top insider-buying stocks.

How do I buy shares of Charles River Laboratories International?

Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Charles River Laboratories International's stock price today?

One share of CRL stock can currently be purchased for approximately $327.70.

How much money does Charles River Laboratories International make?

Charles River Laboratories International has a market capitalization of $16.45 billion and generates $2.62 billion in revenue each year. The medical research company earns $252.02 million in net income (profit) each year or $6.73 on an earnings per share basis.

How many employees does Charles River Laboratories International have?

Charles River Laboratories International employs 18,400 workers across the globe.

Does Charles River Laboratories International have any subsidiaries?

The following companies are subsidiares of Charles River Laboratories International: 3313290 Nova Scotia Company, 9904140 Canada Inc., Accugenix Inc., Agilux Laboratories, Argenta Discovery 2009 Limited, Ballardvale C.V., Beijing Vital River Laboratory Animal Technology Co. Ltd., BioFocus DPI (Holdings) Ltd., Biological Laboratories Europe Ltd. ("BioLabs"), Blue Stream Laboratories, Brains On-Line, CRL Dutch Holding Company B.V., CRL Group France, CRL Group International France, CRL Holding Germany GmbH, CRL Holding Netherlands B.V., CRL Safety Assessment Inc., Celsis Group Limited, Celsis International, Celsis International B.V., Celsis International GmbH, Celsis International Limited, Celsis Limited, Cerebricon, Chantest, Charles River Detecção Microbiana e de Endotoxina Participações Ltda, Charles River Discovery Research Services Finland, Charles River Discovery Research Services Germany GmbH, Charles River Discovery Research Services Inc., Charles River Discovery Research Services International Inc., Charles River Discovery Research Services UK Limited, Charles River Endotoxin Microbial Detection Europe SAS, Charles River Endotoxin and Microbial Detection Israel, Charles River Endotoxin and Microbial Detection Singapore Pte. Ltd., Charles River Germany GmbH & Co. KG, Charles River Germany Verwaltungs GmbH, Charles River Holdings LLC, Charles River Laboratories Ashland LLC, Charles River Laboratories Asia Holdings Limited, Charles River Laboratories Australia Pty. Ltd., Charles River Laboratories Belgium SPRL, Charles River Laboratories Cleveland Inc., Charles River Laboratories Copenhagen, Charles River Laboratories Den Bosch B.V., Charles River Laboratories Edinburgh Ltd., Charles River Laboratories España SA, Charles River Laboratories Evreux, Charles River Laboratories France Safety Assessment SAS, Charles River Laboratories France-C.R.L.F. SAS, Charles River Laboratories Germany GmbH, Charles River Laboratories Group, Charles River Laboratories Holding Europe SAS, Charles River Laboratories Holding SAS, Charles River Laboratories Holdings Limited, Charles River Laboratories Hungary, Charles River Laboratories I Delaware Holdings Inc., Charles River Laboratories II Delaware Holdings Inc., Charles River Laboratories Inc., Charles River Laboratories India Private Limited, Charles River Laboratories Ireland Holding Unlimited Company, Charles River Laboratories Ireland Limited, Charles River Laboratories Italia Srl, Charles River Laboratories Japan Inc., Charles River Laboratories Korea, Charles River Laboratories Luxembourg S.a.r.l., Charles River Laboratories Montreal ULC, Charles River Laboratories Poland Sp. Z.o.o., Charles River Laboratories Research Models and Services Germany GmbH, Charles River Laboratories SA France Acquisition SAS, Charles River Laboratories SA France Holdings SAS, Charles River Laboratories SA Japan KK, Charles River Laboratories SA Netherlands Holdings B.V., Charles River Laboratories SA USA Inc., Charles River Laboratories Saint Nazaire, Charles River Laboratories Saint‑Constant S.A., Charles River Microbial Solutions Company (Shanghai) Limited, Charles River Microbial Solutions International Limited, Charles River Nederland B.V., Charles River UK Limited, Charles River ULC, CiToxLAB, Citox Inc., Citoxlab USA LLC, Genetic Models, HemaCare, Inveresk Research, KWS BioTest, KWS BioTest Limited, MPI Research, Molecular Therapeutics, Nastor Investments, NewLab BioQuality AG, Northwest Kinetics, Oncotest, Pathology Associates International Corporation, Piedmont Research Center, Primedica, River Valley Farms, Saothorlanna Bitheolaiocha Idirnaisiunta Teoranta, Sierra Biomedical, Solvo Biotechnology USA Inc., Solvo Biotechnológiai Zrt, Springborn Laboratories, Sunrise Farms Inc., Systems Pathology Company LLC, WIL Research, Zhanjiang A&C Biological Ltd., and Zhejiang Vital River Laboratory Animal Technology Co. Ltd..

When was Charles River Laboratories International founded?

Charles River Laboratories International was founded in 1947.

What is Charles River Laboratories International's official website?

The official website for Charles River Laboratories International is www.criver.com.

Where are Charles River Laboratories International's headquarters?

Charles River Laboratories International is headquartered at 251 BALLARDVALE STREET, WILMINGTON MA, 01887.

How can I contact Charles River Laboratories International?

Charles River Laboratories International's mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at 781-222-6000 or via email at [email protected]


This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.